BZAD01

Research use only, not for human use.

BZAD01 is a selective NMDA NR1A/2B receptor antagonist.

BZAD01 is a selective NMDA NR1A/2B receptor antagonist.(In Vivo):Parkinsonism was induced by microinjection of the toxin, 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) of 40 Sprague-Dawley rats. Parkinsonism and the efficacy of drugs were assessed using a battery of behavioural tests including balance beam, apomorphine-induced rotation, body axis bias or "curling", head position bias and disengage sensorimotor latency test. The main effects were that BZAD01 co-administration prevented chronic levodopa-induced potentiation of apomorphine rotation. However levodopa-treated rats were slower than either controls or BZAD-01-treated rats in the locomotor test.

——

——

BZAD-01 | BZAD 01

Membrane Transporter/Ion Channel

NMDAR

Guanylate cyclase

——

——

305339-41-7

362.275

C16H12F6N2O

>98% (HPLC)

In Vitro:?Methanol : 250 mg/mL (690.09 )

FC(F)(F)Oc1ccc(cc1)C(=N)NCc1ccccc1C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years